Assessment of efficacy and systemic safety of a new chlorofluorocarbon-free formulation of inhaled beclomethasone dipropionate in asthmatic children

Pediatric Asthma, Allergy and Immunology

Volumn 15, Issue 3, 2001, Pages 133-143

  Lee, T L ^a   Adler, L ^b   McLaren, G ^c   Rossetti, A ^d   Cantini, L ^d  

^a Sheepcot Medical Centre   (United Kingdom)

^b Belmont Health Centre   (United Kingdom)

^c The Surgery   (United Kingdom)

^d CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; PROPELLANT;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; STEROID THERAPY; TASTE DISORDER; VITAL CAPACITY;

EID: 0035744608     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/08831870260093852     Document Type: Article

References (14)

1. CFCs and inhalers
2. The British Guidelines on asthma management, 1995. Review and position statement
3. Air pollution in the 1990s - Cause of increased respiratory disease?
4. Results of co-ordinated review of 1, 1, 1, 2-tetrafluorethane HFAQ-134a
5. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane - Beclomethasone extrafine inhalation aerosol), in asthma
6. Modulation of aerosol clouds produced by pressurised inhalation aerosols
7. Lung volumes and forced ventilatory flows
8. Cumulative dose-response study of non-CFC propellant HFA-134a salbutamol sulfate MDI in patients with asthma
9. A three month multinational study comparing the efficacy and tolerability of salmeterol propelled by chlorofluorocarbons 11 and 12 or an alternative propellant, GR 106642X in children with asthma
10. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma
11. Holding chambers for pMDIs use
12. Equivalence of hydrofluoroalkane (HFA) and chlorofluorocarbons (CFC) formulations of inhaled beclomethasone